专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP3481404A1 METHODS FOR TREATING CUTANEOUS T-CELL LYMPHOMA (CTCL) WITH MIR-155 INHIBITORS 审中-公开
公开(公告)号：EP3481404A1
公开(公告)日：2019-05-15
申请号：EP17825019.7
申请日：2017-07-07
申请人： Miragen Therapeutics, Inc.
发明人： JACKSON, Aimee L. , MARSHALL, William S.
IPC分类号： A61K31/7088 , A61K48/00 , C07H21/02 , C07H21/04 , C12N15/11 , C12N15/113

2. 发明授权

EP2427472B1 LIPOPHILIC POLYNUCLEOTIDE CONJUGATES 有权
标题翻译：亲脂性多核苷酸缀合物
公开(公告)号：EP2427472B1
公开(公告)日：2016-06-22
申请号：EP10772765.3
申请日：2010-05-05
申请人： Miragen Therapeutics
发明人： MARSHALL, William S. , VAGLE, Kurt
IPC分类号： C07J41/00 , C07J43/00 , C07J51/00 , A61K48/00 , A61K31/58
CPC分类号： C07J41/0055 , A61K48/0033 , C07J43/003 , C07J51/00 , C12N15/111 , C12N15/113 , C12N15/87 , C12N2310/113 , C12N2310/315 , C12N2310/3515

3. 发明公开

EP2635681A1 BASE MODIFIED OLIGONUCLEOTIDES 有权
标题翻译：与修饰碱基的寡核苷酸
公开(公告)号：EP2635681A1
公开(公告)日：2013-09-11
申请号：EP11838938.6
申请日：2011-11-07
申请人： Miragen Therapeutics
发明人： VAGLE, Kurt , DALBY, Christina , MARSHALL, William S.
IPC分类号： C12N15/11
CPC分类号： C12N15/113 , C12N15/111 , C12N2310/141 , C12N2310/321 , C12N2310/322 , C12N2310/3231 , C12N2310/33 , C12N2310/3521 , C12N2310/3523 , C12N2310/3525 , C12N2310/3527 , C12N2310/3529 , C12N2320/52
摘要： The present invention relates to oligonucleotides with base modified nucleosides for enhancement of binding affinity.

4. 发明授权

EP2635681B1 BASE MODIFIED OLIGONUCLEOTIDES 有权
公开(公告)号：EP2635681B1
公开(公告)日：2017-08-23
申请号：EP11838938.6
申请日：2011-11-07
申请人： Miragen Therapeutics
发明人： VAGLE, Kurt , DALBY, Christina , MARSHALL, William S.
IPC分类号： C12N15/113
CPC分类号： C12N15/113 , C12N15/111 , C12N2310/141 , C12N2310/321 , C12N2310/322 , C12N2310/3231 , C12N2310/33 , C12N2310/3521 , C12N2310/3523 , C12N2310/3525 , C12N2310/3527 , C12N2310/3529 , C12N2320/52

5. 发明公开

EP2427472A1 LIPOPHILIC POLYNUCLEOTIDE CONJUGATES 有权
标题翻译：亲脂性多核苷酸缀合物
公开(公告)号：EP2427472A1
公开(公告)日：2012-03-14
申请号：EP10772765.3
申请日：2010-05-05
申请人： Miragen Therapeutics
发明人： MARSHALL, William S. , VAGLE, Kurt
IPC分类号： C07H21/00
CPC分类号： C07J41/0055 , A61K48/0033 , C07J43/003 , C07J51/00 , C12N15/111 , C12N15/113 , C12N15/87 , C12N2310/113 , C12N2310/315 , C12N2310/3515
摘要： Disclosed are lipophilic polynucleotide conjugates including polynucleotide-cholesterol conjugates and methods of delivering therapeutic polynucleotides to a mammalian cell or patient in need of treatment using said conjugates. The disclosure further provides methods of synthesizing the lipophilic polynucleotide conjugates.The conjugates are designed to mimic or target cellular miRNAs. The lipophilic moiety, such as cholesterol or cholesterol derivative, is spaced from the polynucleotide by a substantially linear hydrocarbon group. Due to an absence of significantly polar groups and/or exchangeable protons in the vicinity of the lipophilic moiety, the interaction between the lipophilic moiety and cell membranes is enhanced to provide for efficient entry into cells.
摘要翻译：公开了包含多核苷酸 - 胆固醇缀合物的亲脂性多核苷酸缀合物和将治疗性多核苷酸递送至需要使用所述缀合物治疗的哺乳动物细胞或患者的方法。本公开进一步提供了合成亲脂性多核苷酸缀合物的方法。缀合物被设计为模拟或靶向细胞miRNA。亲脂性部分，例如胆固醇或胆固醇衍生物，与多核苷酸间隔基本线性的烃基。由于在亲脂性部分附近缺乏显着的极性基团和/或可交换的质子，亲脂性部分和细胞膜之间的相互作用得到增强以提供有效进入细胞。

6. 发明授权

EP2635681B8 BASE MODIFIED OLIGONUCLEOTIDES 有权
标题翻译：基础修饰的寡核苷酸
公开(公告)号：EP2635681B8
公开(公告)日：2017-10-04
申请号：EP11838938.6
申请日：2011-11-07
申请人： Miragen Therapeutics, Inc.
发明人： VAGLE, Kurt , DALBY, Christina , MARSHALL, William S.
IPC分类号： C12N15/113
CPC分类号： C12N15/113 , C12N15/111 , C12N2310/141 , C12N2310/321 , C12N2310/322 , C12N2310/3231 , C12N2310/33 , C12N2310/3521 , C12N2310/3523 , C12N2310/3525 , C12N2310/3527 , C12N2310/3529 , C12N2320/52

7. 发明公开

EP2652151A2 MICRORNA INHIBITORS COMPRISING LOCKED NUCLEOTIDES 审中-公开
标题翻译：已阻止微小RNA的核苷酸抑制剂
公开(公告)号：EP2652151A2
公开(公告)日：2013-10-23
申请号：EP11820901.4
申请日：2011-12-15
申请人： Miragen Therapeutics
发明人： DALBY, Christina , MARSHALL, William S. , ROOIJ, Eva Van , MONTGOMERY, Rusty
IPC分类号： C12Q1/68
CPC分类号： C12N15/113 , A61K31/7105 , C12N2310/113 , C12N2310/315 , C12N2310/3231 , C12N2310/346 , C12Q2600/178
摘要： The invention provides chemically modified oligonucleotides capable of inhibiting the expression (e.g., abundance) of miR-208 family miRNAs, including miR-208a, miR-208b, and/or miR-499. The invention provides in some embodiments, oligonucleotides capable of inhibiting, in a specific fashion, the expression or abundance of each of miR-208a, miR-208b, and miR-499. The invention further provides pharmaceutical compositions comprising the oligonucleotides, and methods of treating patients having conditions or disorders relating to or involving a miR-208 family miRNA, such as a cardiovascular condition. In various embodiments, the oligonucleotides provide advantages in one or more of potency, efficiency of delivery, target specificity, toxicity, and/or stability.

8. 发明公开

EP2440566A1 CHEMICAL MODIFICATION MOTIFS FOR miRNA INHIBITORS AND MIMETICS 审中-公开
标题翻译：化学改性动机对于miRNA抑制剂和-MIMMETIKA
公开(公告)号：EP2440566A1
公开(公告)日：2012-04-18
申请号：EP10786712.9
申请日：2010-06-08
申请人： Miragen Therapeutics
发明人： YAMADA, Christina , MARSHALL, William S.
IPC分类号： C07H21/04 , C12N15/11
CPC分类号： C12N15/113 , C12N2310/113 , C12N2310/141 , C12N2310/315 , C12N2310/317 , C12N2310/321 , C12N2310/322 , C12N2310/332 , C12N2310/344
摘要： The present invention provides polynucleotides having chemistry patterns that provide for improved stability, potency, and/or toxicity relative to their use as miRNA inhibitors or miRNA mimetics. The invention further provides pharmaceutical compositions and formulations comprising the polynucleotides, and methods for treating patients having a condition associated with miRNA or mRNA expression.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式